Here are seven updates on GI companies from the past week:
Theravance Biopharma revealed early data from its phase 1b clinical trial for its ulcerative colitis drug TD-1473.
Allergan reported second quarter fiscal year 2017 revenues of $4 billion on Aug. 8.
RD Biomed registered its reflux disease testing device Peptest with the FDA.
The Independent Data Monitoring Committee completed a planned analysis of the first half of Celsion's phase III study of ThermoDox, its liver cancer drug. The committee recommended the study continue to completion with no modifications.
The European Commission awarded Bayer marketing authorization for its second line liver cancer treatment Stivarga.
Ironwood Pharmaceuticals reported second quarter fiscal year 2017 revenues of $65.1 billion.
The FDA approved AbbVie's Mavyret chronic hepatitis C virus treatment.